SCHEMBL6824619

SCHEMBL6824619

COc1ccn2nc(-c3ccc(F)cc3)c(-c3ccc(=O)[nH]n3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
MAPK14 Q16539 2/20 0.43
PDE4B Q07343 4/20 0.41
PDE4A P27815 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4D Q08499 3/20 0.41
PDE3A Q14432 6/20 0.41
PDE5A O76074 1/20 0.41
PDE3B Q13370 4/20 0.39
TP53 P04637 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818685 0.89 PDE3A (0.47) LMNAMAPK14PDE4BPDE4APDE4C
SCHEMBL6821911 0.84 PDE3A (0.44) LMNAPDE4BPDE4APDE4CPDE4D
SCHEMBL6822166 0.82 MAPK14 (0.44) LMNAMAPK14MEN1KMT2ACYP1A2
SCHEMBL8199836 0.80 PDE3A (0.60) LMNAMAPK14PDE4BPDE4APDE4C
SCHEMBL6818465 0.80 MAPK14 (0.42) LMNAMAPK14TP53EGFRRAF1
SCHEMBL6821421 0.80 MAPK14 (0.42) MAPK14MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL6822087 0.78 ADORA1 (0.43) MAPK14PDE4BPDE4APDE4CPDE4D
SCHEMBL7367727 0.78 LMNA (0.53) LMNAPDE4BPDE4APDE4CPDE4D
SCHEMBL8193845 0.77 PDE3A (0.56) LMNAMAPK14PDE4BPDE4APDE4C
SCHEMBL5382141 0.77 MAPK14 (0.72) MAPK14EGFRRAF1ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 LMNA 4472/4885MAPK14 3737/4885PDE4B 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.